Antibody-drug conjugates (ADCs) are therapies that target cancer cells with antigen-specific antibodies and highly toxic payloads. ADCs are currently generating interest among drug developers, contract manufacturing companies, regulatory agencies, and other stakeholders.
• The rise in the number of drug approvals has also sparked interest in further developing this technology, with several companies developing solutions for one or more ADC components.
• The development of technologies is ongoing and will only increase as applications of ADCs increasingly expand into non-oncologic indications.
• It provides an overview of key technology platforms, patents, analytical techniques, and manufacturing developments, covering the various technological advancements that may see adoption in ADC development.
Sign up for a complimentary Growth Pipeline Dialog™
A Growth Pipeline Dialog is a structured open discussion with our growth experts providing unparalleled industry intelligence, technology advancements, and proven implementation best practices. This discussion will spark innovative thinking and help generate a pipeline of growth opportunities you can leverage to maximize your company’s future growth potential.